CJC-1295 + Ipamorelin
Mod GRF(1-29) + Ipamorelin · CJC no-DAC + Ipa · GHRH+GHRP blend
ANECDOTAL + ANIMAL STUDIES · GHRH ANALOG + SELECTIVE GHRP BLEND (GH-SECRETAGOGUE STACK)
▓ 5 indexed citations across EuropePMC (5).
Citation breakdown by evidence tier
← weaker evidence · stronger evidence →
Tap any tier to jump to that section of the bibliography.
Mechanism of action
Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm).
Researched effects
Layered pituitary GH release; improved sleep architecture; recovery and lean body composition support; lower cortisol/prolactin signal than GHRH + GHRP-6 alternatives
Live evidence
Recent literature
Live signals refreshed daily. Current as of November 19, 2026.
Dosing reported in literature
100 mcg of each component SC nightly (5 nights/wk); some protocols use 200 mcg of each pre-sleep. Cycle 8-12 weeks on / 4 weeks off
Known concerns
Receptor desensitisation with chronic daily dosing; mild water retention; injection site reactions; theoretical IGF-1 elevation with high-frequency dosing; not FDA-approved for any indication
Top-ranked picks
5 pre-curated authoritative sources, ranked by journal tier and study weight.
- Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.
- Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
- Injuries, Injections, and Internet Forums: A Qualitative Study of Reddit User Perspectives on Peptide Therapy After Orthopaedic Surgery.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Full citation library
Year distribution
No references match — clear filters.
Research Articles
5-
1.
<h4>Background</h4>Injectable peptides are increasingly promoted for musculoskeletal recovery, tissue repair, and performance enhancements; however, clinical adoption has outpaced high-quality evidence and regulatory consensus.<h4>Purpose</h4>To summarize contemporary human and translational evidence (January 1, 2020-August 31, 2025) for injectable peptides relevant to orthopaedics and sports medicine, and to clarify safety, product quality, regulatory, antidoping implications, and clinical outc…
-
2.
<h4>Background</h4>Peptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline.<h4>Objective</h4>To comprehensively review the mechanisms, clinical applications, evidence base, and safety profiles of therapeutic peptides with demonstrated or potential applications in healthy aging and age-related conditions.<h4>Methods</h4>A comprehensiv…
-
3.
<h4>Background</h4>Therapeutic peptides are short-chain amino acids that regulate cellular functions and facilitate biochemical processes. In recent years, there has been significant growth in the global market for therapeutic peptides and thus its popularity among patients. Given the increase in the development of peptides and increased marketing to patients for orthopaedic injuries, it is critical for orthopaedic surgeons to understand the current evidence behind these therapeutic peptides.<h4…
- 4.
-
5.
Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, grounded in their ability to modulate molecular signaling networks central to cellular medicine. By acting on key pathways such as PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK, peptides exert influence over tissue regeneration, inflammation resolution, and neuromuscular recovery. Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodel…
Curated sources on file
3- 1.
- 2.
- 3.